Shanghai Nianxing Industrial Co., Ltd
China
Product Name: CTCE9908TFA
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

DC Chemicals Limited
China
Product Name: CTCE-9908
Price: ￥Inquiry/1g
Purity: 98.9%
Stocking Period: 1 Day
Contact: Tony Cao
Email: sales@dcchemicals.com

1030384-98-5

1030384-98-5 structure

1030384-98-5 structure

Name: CTCE 9908 TFA
Chemical Name: NF0BX95A31
CAS Number: 1030384-98-5
Molecular Formula: C₈₆H₁₄₇N₂₇O₂₃
Molecular Weight: 2041.25
Catalog: Signaling Pathways GPCR/G Protein CXCR
Create Date: 2018-06-21 22:42:07
Modify Date: 2025-09-13 19:01:37
CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, inhibits migration and induces cytotoxicity in CXCR4-expressing ovarian cancer cells[1][2].

Name	NF0BX95A31
Synonyms	NF0BX95A31

Description	CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, inhibits migration and induces cytotoxicity in CXCR4-expressing ovarian cancer cells[1][2].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> GPCR/G Protein >> CXCR Signaling Pathways >> Immunology/Inflammation >> CXCR
Target	CXCR4
In Vitro	CTCE-9908 (0-300 μg/mL; for 10 d) inhibits migration and growth in CXCR4-expressing in ovarian cancer cell lines (IGROV, TOV21G and SKOV3). CTCE-9908 inhibits ovarian cancer cell migration to CXCL12. CTCE-9908 does not cause apoptosis or cellular senescence, but induces multinucleation, G2-M arrest, and abnormal mitosis in ovarian cancer cells. CTCE-9908 deregulates DNA damage checkpoint proteins and spindle assembly checkpoint proteins at G2-M phases of the cell cycle[1].
In Vivo	CTCE-9908 (25, 50 and 100 mg/kg; s.c.; 5 days per week for 4.5 weeks) alone slows the rate of primary breast tumor growth, with a 45% inhibition of primary tumor growth at 3.5 weeks of treatment with 50 mg/kg of CTCE-9908 in FVB/N TgN (MMTV-PyMT)634 male mice[2].
References	[1]. Joseph Kwong, et al. An antagonist of the chemokine receptor CXCR4 induces mitotic catastrophe in ovarian cancer cells. Mol Cancer Ther. 2009 Jul;8(7):1893-905. [2]. Saima Hassan, et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int J Cancer. 2011 Jul 1;129(1):225-32.

Molecular Formula	C₈₆H₁₄₇N₂₇O₂₃
Molecular Weight	2041.25
Storage condition	-20°C

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.